Onswik weekly insulin authorized for type 2 diabetes

The Medicines and Healthcare products Regulatory Agency (MHRA) has authorized Onswik (insulin efsitora alfa) for the treatment of type 2 diabetes in adults. This long-acting basal insulin is administered via a once-weekly injection, which may reduce the annual number of injections from 365 to 52 for some patients.

Clinical trial data indicates that the weekly insulin provides glycemic control comparable to traditional once-daily basal insulin treatments. The medication utilizes a slow-release mechanism where insulin molecules attach to albumin in the blood and bind to a fat molecule to ensure a steady stream of insulin over approximately seven to eight days.

The National Institute for Health and Care Excellence (NICE) has also issued guidance recommending Onswik as an option for certain adults with the condition. While the treatment offers improved convenience, medical professionals note that because the medication remains active for a full week, recovering from accidental hypoglycemia (low blood sugar) may take longer than with daily options.